Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Photo: Gregers Tycho/ERH

Chairman of the board at Lundbeck Lars Rasmussen is piling on the pressure by criticizing the company in the middle of a share price fiasco, while a growth crisis looms on the horizon.

"There is no doubt that it is disappointing that none of the treatments we had in the pipeline years ago have made it to the market. The poor internal success rate is definitely something that requires consideration," he says.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs